PDL BIOPHARMA INC's ticker is and the CUSIP is 69329YAJ3. A total of 8 filers reported holding PDL BIOPHARMA INC in Q3 2019. The put-call ratio across all filers is - and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $2,129,425,000 | +83.8% | 2,000,000 | +100.0% | 0.49% | -12.1% |
| Q2 2020 | $1,158,800,000 | +3.0% | 1,000,000 | 0.0% | 0.55% | -14.3% |
| Q1 2020 | $1,125,470,000 | +1.5% | 1,000,000 | 0.0% | 0.64% | +55.0% |
| Q4 2019 | $1,108,510,000 | +19.1% | 1,000,000 | 0.0% | 0.42% | +18.5% |
| Q3 2019 | $930,625,000 | – | 1,000,000 | – | 0.35% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Context Capital Management, LLC | 10,344,000 | $9,921,000 | 5.62% |
| Soros Fund Management | 17,624,000 | $16,577,000 | 0.46% |
| Pinnacle Holdings, LLC | 1,000,000 | $930,625,000 | 0.35% |
| WOLVERINE ASSET MANAGEMENT LLC | 11,852,000 | $11,136,000 | 0.14% |
| LAZARD ASSET MANAGEMENT LLC | 12,000,000 | $11,287,000 | 0.02% |
| Citadel Advisors | 22,733,000 | $21,352,000 | 0.01% |
| DEUTSCHE BANK AG\ | 10,500,000 | $9,771,000 | 0.01% |
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. | 0 | $0 | 0.00% |